Developer docs
API playgroundTry for free, no card

Search company profiles

Sabai Global

Full company profile

uuid0008nsq

Namestring
Sabai Global
Legal namestring
Sabai Global
Websiteurl
sabaiglobal.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Sabai Global is a US-based regulatory and biosafety review services provider focused on clinical trials, with particular depth in cell and gene therapy. The company delivers Institutional Review Board (IRB) services — AAHRPP-accredited ethical review across therapeutic areas — and Institutional Biosafety Committee (IBC) review services tailored to gene and cell therapy protocols, where biosafety risk assessment is a regulatory requirement. It also offers biosafety consulting, including a proprietary facility-specific emergency response methodology called BioWOPER™, originally co-developed with Sanofi. Clients include biotech and pharmaceutical sponsors, contract research organizations (CROs), and academic medical centers; named enterprise customers include Merck, MedPace, Emmes, CenExel, the University of California-San Diego, and Seattle Children's Hospital.

Sabai's technology stack centers on its MySabai IRB and IBC portals for electronic submission, review, and tracking, combined with deep human expertise (it claims the largest concentration of credentialed biosafety professionals globally). The company was formed through a 2018 founding and grew via the consolidation of three subsidiaries — Castle IRB, CBS IBC, and Shield Consulting — which were unified under the Sabai Global brand in October 2024. A January 2024 acquisition of Alpha Independent Review Board further broadened its IRB footprint. The company is privately held and received a growth investment from Thompson Street Capital Partners (TSCP) in February 2023.

Revenue is generated through three streams: recurring IRB review services (subscription-style engagements), recurring IBC review services for cell and gene therapy trials, and professional services consulting including BioWOPER planning. Pricing is quote-based and not publicly disclosed. Go-to-market is enterprise field sales targeting biotech and pharma sponsors and CROs, supported by content marketing (blog, white papers, webinars) and partnerships with industry media such as Xtalks. The company operates from a single headquarters in Chesterfield, Missouri, and serves a US-domestic market.

Short descriptiontext

Sabai Global is a US-based, AAHRPP-accredited provider of IRB and IBC review services for clinical trials, with particular specialization in cell and gene therapy biosafety. It serves biotech and pharma sponsors, CROs, and academic medical centers through a unified portal-based platform and biosafety consulting.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersChesterfield, United States
HQ citystring
Chesterfield
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
IRB review services, IBC review services, biosafety consulting, clinical trial compliance, ethical review services
Industry5 codes
PRIMARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAG
Medical Writing & Regulatory Submission Support CROs
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Other Scientific and Technical Consulting Services541690
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Management Consulting Services8742
Product category
Clinical Research Compliance Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1IRB Review Services
TypeSubscription Recurring
Description

AAHRPP-accredited ethical review services for clinical research across all therapeutic areas, providing study review, principal investigator assessments, and regulatory advice.

sabaiglobal.com
2IBC Review Services
TypeSubscription Recurring
Description

Institutional biosafety committee review services for cell and gene therapy clinical trials, including biosafety guidance, risk assessments, and concierge services.

sabaiglobal.com
3Biosafety Consulting
TypeProfessional Services
Description

Strategic consulting services for regulatory compliance, emergency preparedness (BioWOPER), and operational support for biotech and pharma clients.

sabaiglobal.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1MySabai IRB Portal
Description

Online portal for IRB services access and management

sabaiglobal.com
+5 more records
Core offering1 text field

Sabai Global provides AAHRPP-accredited Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review services for clinical trials, with deep specialization in cell and gene therapy. The company delivers ethical review, biosafety guidance, risk assessments, and concierge support to biotech and pharmaceutical sponsors, contract research organizations (CROs), and research institutions across the United States.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Reduced site activation timeline with same-day turnaround on multi-page IBC question lists (less than 2 hours)
+1 more record
Product overview1 text field

Sabai Global is a unified platform providing AAHRPP-accredited Institutional Review Board (IRB) services and Institutional Biosafety Committee (IBC) services for clinical trials, particularly specializing in cell and gene therapy. The company operates through its core service offerings: Sabai IRB Services (ethical review for multi-therapeutic research) and Sabai IBC Services (centralized biosafety reviews for cell and gene therapy). Former subsidiaries Castle IRB, CBS IBC, and Shield Consulting were consolidated under the Sabai Global brand in October 2024. The company also acquired Alpha Independent Review Board (January 2024) to expand its regulatory review capabilities. Clients access services through MySabai IRB Portal and MySabai IBC Portal. Additional offerings include BioWOPER™ (biosafety emergency response planning and training) and specialized consulting services.

Product and service1 record
1Sabai IRB Services
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Xtalks
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-11-07
Description

Xtalks, a life sciences webinar platform, hosted a webinar featuring industry leaders from Pfizer and Sabai Global discussing best practices for collaboration between sponsors, CROs, and IRBs to accelerate approval processes.

prnewswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-10
Description

Sabai Group LLC completed acquisition of Alpha Independent Review Board, LLC, a provider of IRB services for clinical trials. The acquisition expands Sabai's capabilities in biosafety, human research protections, and regulatory review for biotech and pharma clients.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

The BioWOPER methodology was conceived jointly by team members from Sanofi and Sabai. BioWOPER is a customized biosafety emergency response planning and training methodology developed through collaboration between the two organizations.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Genezen is a gene and cell therapy focused services and consulting company. While primarily a CDMO, it provides biosafety and regulatory support overlapping with Sabai's IBC and BioWOPER services for advanced therapy developers.

TypeBroad incumbent
Description

IQVIA is a global CRO and clinical research services giant offering full-service trial management. While not an IRB, it competes upstream with integrated offerings that include central IRB/IBC coordination, overlapping with Sabai's CRO-facing GTM.

TypeDirect peer
Description

Sterling IRB is an AAHRPP-accredited independent IRB providing central ethics review services for clinical trials. It is a comparable specialty IRB competing for the same biotech and CRO client base.

4Pearl IRB
TypeEmerging player
Description

Pearl IRB is an independent IRB serving medical device, pharmaceutical, and biologics trials. It is an emerging direct competitor in the same central IRB market niche as Sabai, with a focus on quality and customer service.

TypeBroad incumbent
Description

Fortrea (spun out from Labcorp) is a major CRO offering central lab and clinical development services. It is a broad incumbent in the clinical research services space that touches Sabai's sponsor and CRO customer base.

TypeDirect peer
Description

Advarra is a leading AAHRPP-accredited independent IRB serving pharma, biotech, and CROs across all therapeutic areas. It is the most direct head-to-head competitor to Sabai's IRB and IBC review services, with overlapping enterprise customers and similar GTM.

TypeBroad incumbent
Description

ICON is a top global CRO providing clinical trial services to pharma and biotech. Like IQVIA, it competes with Sabai indirectly by bundling ethics and biosafety review coordination into broader CRO service packages for sponsors.

TypeDirect peer
Description

WCG operates one of the largest independent IRB networks (including WIRB, Copernicus, and Aspire) and offers central IRB services comparable to Sabai. It is a primary direct competitor for multi-site clinical trial ethics review.

TypeBroad incumbent
Description

Charles River Labs provides a broad suite of research models, preclinical, and clinical support services to biotech and pharma. Its biosafety and safety assessment practices overlap with Sabai's consulting and IBC review offerings for advanced therapy sponsors.

TypeDirect peer
Description

BRANY is an AAHRPP-accredited central IRB and IACUC services provider serving academic medical centers and sponsors. It competes with Sabai in IRB services and biosafety committee support, particularly for academic and hybrid sponsor trials.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sabai Global

Clinical Research Compliance Servicessabaiglobal.com

Sabai Global is a US-based, AAHRPP-accredited provider of IRB and IBC review services for clinical trials, with particular specialization in cell and gene therapy biosafety. It serves biotech and pharma sponsors, CROs, and academic medical centers through a unified portal-based platform and biosafety consulting.

What Sabai Global does

Sabai Global is a US-based regulatory and biosafety review services provider focused on clinical trials, with particular depth in cell and gene therapy. The company delivers Institutional Review Board (IRB) services — AAHRPP-accredited ethical review across therapeutic areas — and Institutional Biosafety Committee (IBC) review services tailored to gene and cell therapy protocols, where biosafety risk assessment is a regulatory requirement. It also offers biosafety consulting, including a proprietary facility-specific emergency response methodology called BioWOPER™, originally co-developed with Sanofi. Clients include biotech and pharmaceutical sponsors, contract research organizations (CROs), and academic medical centers; named enterprise customers include Merck, MedPace, Emmes, CenExel, the University of California-San Diego, and Seattle Children's Hospital.

Sabai's technology stack centers on its MySabai IRB and IBC portals for electronic submission, review, and tracking, combined with deep human expertise (it claims the largest concentration of credentialed biosafety professionals globally). The company was formed through a 2018 founding and grew via the consolidation of three subsidiaries — Castle IRB, CBS IBC, and Shield Consulting — which were unified under the Sabai Global brand in October 2024. A January 2024 acquisition of Alpha Independent Review Board further broadened its IRB footprint. The company is privately held and received a growth investment from Thompson Street Capital Partners (TSCP) in February 2023.

Revenue is generated through three streams: recurring IRB review services (subscription-style engagements), recurring IBC review services for cell and gene therapy trials, and professional services consulting including BioWOPER planning. Pricing is quote-based and not publicly disclosed. Go-to-market is enterprise field sales targeting biotech and pharma sponsors and CROs, supported by content marketing (blog, white papers, webinars) and partnerships with industry media such as Xtalks. The company operates from a single headquarters in Chesterfield, Missouri, and serves a US-domestic market.

Sabai Global firmographics

Firmographics
Name
Sabai Global
Legal name
Sabai Global
Website
https://sabaiglobal.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
51–100 employees
Short description
Sabai Global is a US-based, AAHRPP-accredited provider of IRB and IBC review services for clinical trials, with particular specialization in cell and gene therapy biosafety. It serves biotech and pharma sponsors, CROs, and academic medical centers through a unified portal-based platform and biosafety consulting.
Ownership category
akta.pro rank

Sabai Global industry classification

Industry
Product category
Clinical Research Compliance Services
NAICS
Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (541690)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Management Consulting Services (8742)
akta.pro industry
PRIMARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAG
Medical Writing & Regulatory Submission Support CROs
SECONDARYHLAGAAAH
Pharmacovigilance, Risk Management & Medical Affairs CROs
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • IRB review services
  • IBC review services
  • Biosafety consulting
  • Clinical trial compliance
  • Ethical review services

Where Sabai Global is headquartered

Location

Headquarters

HQ city
Chesterfield
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Sabai Global business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. IRB Review Services: AAHRPP-accredited ethical review services for clinical research across all therapeutic areas, providing study review, principal investigator assessments, and regulatory advice.
  2. IBC Review Services: Institutional biosafety committee review services for cell and gene therapy clinical trials, including biosafety guidance, risk assessments, and concierge services.
  3. Biosafety Consulting: Strategic consulting services for regulatory compliance, emergency preparedness (BioWOPER), and operational support for biotech and pharma clients.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Sabai Global product offering

Product offering

Core offering

Sabai Global provides AAHRPP-accredited Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review services for clinical trials, with deep specialization in cell and gene therapy. The company delivers ethical review, biosafety guidance, risk assessments, and concierge support to biotech and pharmaceutical sponsors, contract research organizations (CROs), and research institutions across the United States.

Product overview

Sabai Global is a unified platform providing AAHRPP-accredited Institutional Review Board (IRB) services and Institutional Biosafety Committee (IBC) services for clinical trials, particularly specializing in cell and gene therapy. The company operates through its core service offerings: Sabai IRB Services (ethical review for multi-therapeutic research) and Sabai IBC Services (centralized biosafety reviews for cell and gene therapy). Former subsidiaries Castle IRB, CBS IBC, and Shield Consulting were consolidated under the Sabai Global brand in October 2024. The company also acquired Alpha Independent Review Board (January 2024) to expand its regulatory review capabilities. Clients access services through MySabai IRB Portal and MySabai IBC Portal. Additional offerings include BioWOPER™ (biosafety emergency response planning and training) and specialized consulting services.

Differentiator

Problem solved

Functional benefit

Brands

  • MySabai IRB Portal: Online portal for IRB services access and management
  • MySabai IBC Portal
  • BioWOPER
  • Sabai Compliance
  • Sabai IRB Services
  • Sabai IBC Services

Products and services

  • Sabai IRB Services

Quantifiable outcome

  • Reduced site activation timeline with same-day turnaround on multi-page IBC question lists (less than 2 hours)
  • +1 more outcomes

Companies that use Sabai Global

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Sabai Global technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Sabai Global partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor and core.

  • XtalksminorGTM or Marketing Partner · 7 November 2025Xtalks, a life sciences webinar platform, hosted a webinar featuring industry leaders from Pfizer and Sabai Global discussing best practices for collaboration between sponsors, CROs, and IRBs to accelerate approval processes.
  • Alpha Independent Review Board, LLCcoreStrategic or Co-development Partner · 10 January 2024Sabai Group LLC completed acquisition of Alpha Independent Review Board, LLC, a provider of IRB services for clinical trials. The acquisition expands Sabai's capabilities in biosafety, human research protections, and regulatory review for biotech and pharma clients.
  • SanofiminorStrategic or Co-development PartnerThe BioWOPER methodology was conceived jointly by team members from Sanofi and Sabai. BioWOPER is a customized biosafety emergency response planning and training methodology developed through collaboration between the two organizations.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Sabai Global competitors and assessment

Company assessment

Emerging players

  • Genezen: Genezen is a gene and cell therapy focused services and consulting company. While primarily a CDMO, it provides biosafety and regulatory support overlapping with Sabai's IBC and BioWOPER services for advanced therapy developers.
  • Pearl IRB: Pearl IRB is an independent IRB serving medical device, pharmaceutical, and biologics trials. It is an emerging direct competitor in the same central IRB market niche as Sabai, with a focus on quality and customer service.

Broad incumbents

  • IQVIA: IQVIA is a global CRO and clinical research services giant offering full-service trial management. While not an IRB, it competes upstream with integrated offerings that include central IRB/IBC coordination, overlapping with Sabai's CRO-facing GTM.
  • Labcorp Drug Development (Fortrea): Fortrea (spun out from Labcorp) is a major CRO offering central lab and clinical development services. It is a broad incumbent in the clinical research services space that touches Sabai's sponsor and CRO customer base.
  • ICON plc: ICON is a top global CRO providing clinical trial services to pharma and biotech. Like IQVIA, it competes with Sabai indirectly by bundling ethics and biosafety review coordination into broader CRO service packages for sponsors.
  • Charles River Laboratories: Charles River Labs provides a broad suite of research models, preclinical, and clinical support services to biotech and pharma. Its biosafety and safety assessment practices overlap with Sabai's consulting and IBC review offerings for advanced therapy sponsors.

Direct peers

  • Sterling IRB: Sterling IRB is an AAHRPP-accredited independent IRB providing central ethics review services for clinical trials. It is a comparable specialty IRB competing for the same biotech and CRO client base.
  • Advarra: Advarra is a leading AAHRPP-accredited independent IRB serving pharma, biotech, and CROs across all therapeutic areas. It is the most direct head-to-head competitor to Sabai's IRB and IBC review services, with overlapping enterprise customers and similar GTM.
  • WCG (WIRB-Copernicus Group): WCG operates one of the largest independent IRB networks (including WIRB, Copernicus, and Aspire) and offers central IRB services comparable to Sabai. It is a primary direct competitor for multi-site clinical trial ethics review.
  • BRANY: BRANY is an AAHRPP-accredited central IRB and IACUC services provider serving academic medical centers and sponsors. It competes with Sabai in IRB services and biosafety committee support, particularly for academic and hybrid sponsor trials.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Sabai Global social profiles

Digital presence

Sabai Global compliance and trust

Trust signal

Compliance1 record

Sabai Global financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sabai Global leadership team

Management profile

Number of profiles

Profiles5 records

Sabai Global subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Sabai Global funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sabai Global M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sabai Global

What does Sabai Global do?

Sabai Global provides AAHRPP-accredited Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review services for clinical trials, with deep specialization in cell and gene therapy. The company delivers ethical review, biosafety guidance, risk assessments, and concierge support to biotech and pharmaceutical sponsors, contract research organizations (CROs), and research institutions across the United States.

Is Sabai Global a public or private company?

Sabai Global is a private company. It is classified as private equity controlled and is currently operating.

When was Sabai Global founded?

Sabai Global was founded in 2018. It employs 51 to 100 people.

Where is Sabai Global based?

Sabai Global is headquartered in Chesterfield, United States, in the North America region.

How does Sabai Global make money?

Three revenue lines are on record. IRB Review Services are the primary driver. The others are IBC Review Services and biosafety Consulting.

Who are Sabai Global's main competitors?

Emerging players on record are Genezen and Pearl IRB. Broad incumbents are IQVIA, Labcorp Drug Development (Fortrea), ICON plc and Charles River Laboratories. Direct peers are Sterling IRB, Advarra, WCG (WIRB-Copernicus Group) and BRANY.

Does Sabai Global have an API?

No public API is recorded for Sabai Global.

What industry is Sabai Global in?

Sabai Global's product category is Clinical Research Compliance Services. Its primary akta.pro industry code is HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease), with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireSabai Completes Acquisition of Alpha IRBSabai Group LLC completed the acquisition of Alpha Independent Review Board, LLC, a provider of Institutional Review Board services for clinical trials. The merger combines Alpha IRB's late-stage multi-center review experience with Sabai's early-stage capabilities in oncology and cell-gene therapy to expand regulatory review offerings. Both companies stated that existing contracts remain unchanged and highlighted the strategic fit in their shared patient-first culture.Business Wire BlogThompson Street Capital Partners Completes Growth Investment in Sabai GlobalThompson Street Capital Partners completed a growth investment in Sabai Global, a biosafety and regulatory review firm. Terms were not disclosed, but Sabai's subsidiaries support over 600 Institutional Biosafety Committees and 300 cell and gene therapy trials. The investment aims to support Sabai's expansion in cell and gene therapy.Venture Capital Access OnlineThompson Street Capital Partners Completes Growth Investment in Sabai GlobalThompson Street Capital Partners completed a growth investment in Sabai Global, a provider of regulatory review and biosafety consulting services for the pharmaceutical industry. The undisclosed transaction aims to support Sabai's expansion in supporting clinical research timelines for cell and gene therapy trials. This partnership leverages TSCP's focus on life sciences companies to accelerate Sabai's growth in key therapeutic areas.TscpThompson Street Capital Partners Completes Growth Investment in Sabai GlobalThompson Street Capital Partners has announced a growth investment in Sabai Global, a provider of regulatory review and biosafety consulting services, based in Chesterfield, MO. Sabai Global, which operates three subsidiaries that support clinical research, is set to enhance its capabilities in the growing fields of oncology, rare disease, and infectious disease with TSCP's investment. The partnership is aimed at accelerating clinical research timelines for drug development and expanding Sabai's market presence.PharmiWeb.comThompson Street Capital Partners Completes Growth Investment in Sabai GlobalThompson Street Capital Partners has completed a growth investment in Sabai Global, a provider of regulatory review and biosafety consulting services for the pharmaceutical industry. The financial terms of the transaction were not disclosed, but the investment aims to support Sabai's expansion in the cell and gene therapy market.